Docoh
Loading...

66 results

Filter options loading...
Top filers
Top filing types
Recent filing years
DEF 14A
PCSA Processa Pharmaceuticals Inc
20 Sep 21
Definitive proxy
2:51pm
instructions on how to access this proxy statement and how you may submit your proxy on the internet or by telephone. If you received this notice by mail, you … by mail and wish to access these materials via the internet or electronic delivery in the future, what should I do? If you have previously signed up
PRE 14A
PCSA Processa Pharmaceuticals Inc
1 Sep 21
Preliminary proxy
4:46pm
instructions on how to access this proxy statement and how you may submit your proxy on the internet or by telephone. If you received this notice by mail … materials by mail and wish to access these materials via the internet or electronic delivery in the future, what should I do? If you have previously
8-K
EX-1.1
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
in conformity with generally accepted accounting principles and to maintain accountability for assets; (iii) access to assets is permitted only … supplied by the Company or the Sales Agent, the intent of the parties and their relative knowledge, access to information and opportunity to correct
10-Q
2021 Q2
PCSA Processa Pharmaceuticals Inc
12 Aug 21
Quarterly report
4:01pm
disruption of global financial markets, reducing our ability to access capital, which could negatively affect our liquidity. Policymakers around
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
of the ability to grant to another Person access to such tangible property or access to or a license or sublicense to such intellectual property right or other … . For this purpose, Ocuphire shall execute such legal papers and cooperate in the prosecution of such Action, including providing full access to documents
10-Q
vd3x97vm ejt9
13 May 21
Quarterly report
4:30pm
DEF 14A
qpxpxqs2q9puy no
22 Apr 21
Definitive proxy
2:00pm
10-K/A
qrvzaadhz
7 Apr 21
Annual report (amended)
4:23pm
10-K
dl0k4dl
24 Mar 21
Annual report
8:00pm
8-K
EX-10.1
kjx2yykzpg5xl
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-10.2
pz4dm xr62
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
10-Q
zojfnr
12 Nov 20
Quarterly report
4:01pm
8-K
EX-1.1
ewd7f
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
424B4
22pki25t ht17
5 Oct 20
Prospectus supplement with pricing info
4:16pm
S-1/A
z08ms3ushh5cu
30 Sep 20
IPO registration (amended)
4:06pm
S-1/A
ti02opqc b6sr3
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-2.1
2lute 8kj
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-1.1
fpyuqf
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-3.2
j7dquze
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-10.13
fbn803c0j3r
16 Sep 20
IPO registration (amended)
8:00pm